Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Dividends per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Dividends per Share?

Paradigm Biopharmaceuticals's dividends per share for the six months ended in Dec. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Paradigm Biopharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Paradigm Biopharmaceuticals Dividends per Share Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Dividends per Share Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Dividends per Share

Get a 7-Day Free Trial

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Paradigm Biopharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Dividend Yield % falls into.

Paradigm Biopharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Paradigm Biopharmaceuticals (OTCPK:PBIGF) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Paradigm Biopharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.109
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Paradigm Biopharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).